<?xml version="1.0" encoding="UTF-8"?>
<p id="Par102">A Gen24-generated minimisation program that incorporates a random element will be used to ensure treatment groups are well balanced for specific participant characteristics. For R1 these are: β
 <sub>2</sub>-microglobulin concentration at first relapse (&lt; 3.5, 3.5–&lt; 5.5, ≥ 5.5 mg/L, unknown); length of first remission or plateau (&lt; 18 months, 18–24 months or &gt; 24 months); response to ITD re-induction therapy (&lt; VGPR or ≥ VGPR); cytogenetic risk status at trial entry (Standard Risk, High-Risk or Unknown), as defined by Palumbo et al., in the presence of del(17p) and/or translocation t(4;14), and/or translocation t(14;16) [
 <xref ref-type="bibr" rid="CR25">25</xref>] and maintenance treatment received in first-line setting (Yes or No).
</p>
